Cysteine-Rich Protein Prevents Weight Loss in Lung Cancer Patients
Immunotec Inc. announced the successful completion of a multi-center randomized, double-blind clinical trial on cancer-related weight loss (cachexia) in lung cancer patients which was performed in collaboration with various Canadian clinical centers. The research concluded that patients treated with IMN 1207 showed significant increases in body weight (Tozer et al. antioxidants & Redox Signaling (2008) 10:395-402). Immunotec also announced the initiation of a follow-up study to confirm the positive results.
The massive loss of body weight and muscle mass in advanced cancer patients is typically associated with psychological stress, financial burden and a decreased quality of life. Until now there have been no dietary interventions known to satisfactorily prevent this process.
Immunotec's new study included 66 patients with advanced lung cancer receiving state of the art chemotherapy or radiotherapy. The patients had already suffered significant involuntary weight-loss prior to treatment. During a six month treatment period the patients were given either casein, a protein supplement low in cysteine which is widely used in clinical nutrition ("placebo") or IMN 1207, a specially-prepared glutathione enhancing cysteine-rich whey protein isolate supplied by Immunotec Inc. The results showed that patients in the placebo group continued to lose weight whereas patients treated with IMN 1207 showed a significant increase in body weight. Incidentally, these patients also showed an increase in strength and quality of life parameters. This study showed for the first time that cancer-related weight loss (cachexia) can be prevented by a single source of protein.
Among other questions, this clinical trial also addressed the controversy about antioxidant use in chemotherapy. Since radiotherapy and many types of chemotherapy work by raising levels of oxidative stress and free radical formation to destroy cancer cells, oncologists have voiced concern that treatment of the patient with antioxidants may "protect" the cancer from the toxic effects of the therapy. If this were the case, antioxidants could even be expected to shorten the life span of the patients. Immunotec's study now showed that this was clearly not the case with IMN 1207. Based on his earlier work at his laboratory at the National Cancer Research Center of Germany (DKFZ) in Heidelberg, Dr. Drvge was reasonably confident that supplementation with a critical precursor of the major cellular antioxidant glutathione, would actually improve the condition of the patients, most probably by ameliorating adverse effects of these therapies on the patients' healthy tissues. The results of this new study suggest that this is true. The antioxidant glutathione is distinct from other antioxidants including the popular antioxidant vitamins A, C, and E which are widely used as nutritional supplements. Glutathione is involved in the removal of reactive oxygen species and other potential toxic compounds through special biochemical processes and can reach relatively high and beneficial concentrations in cells and tissues depending on the availability of its biosynthetic precursor cysteine.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
QIAGEN Completes Management Buyout of its Synthetic DNA Business Unit - QIAGEN to Keep its siRNA Business and to Retain Preferred Access to Synthetic DNA Supply
Anika Therapeutics Announces Termination of Worldwide Development and Commercialization Partnership with OrthoNeutrogena - Company Files Pre-Market Approval Applicaton for Cosmetic Tissue Augmentation Product
Plymoth-Plymex GmbH - Bad Honnef, Germany
Viron reports positive proof of concept results in arthritis for its VT-346 anti-TNF therapeutic
Horizon Discovery Expands Commercial Division with Senior Appointments
Prometic Finalizes Major Technology Licencing Agreement in Tunisia
pluriSelect GmbH - Leipzig, Germany
Faster method to create antibodies for disease research
Pharminox signs option to in-license novel telomere signalling targeted agents from Cancer Research Technology
To-BBB announces collaboration with Genzyme on brain delivery of biologics for neurodegenerative diseases
